This was explained as the patchy nature of dystrophin production via exon skipping and the relatively small piece of muscle biopsy could miss this patchy expression. So reading to deeply into a subject showing 0 for one sample could show something dramatically different with another.
Steve Wilton gave some good insight of his views on the 4th biopsy protocols during Oct 1st data release if i recall correctly.
I don't have them to reference specifically without searching for it but I believe the FDA wanted them run to their guidelines and dismissed any higher figures not run to their protocol.
They did western blots before yes. FDA wanted more strict criteria around western blotting methods with 4th biopsy.
For Ed at this point in his career I don't think it is as much about the money as it is for the research but the timing is a bit off for me.
Not too sure what if any relevance this has but did come out today after hours.
How many patients do you think SRPT has that have baseline and 48 week biopsy data on from the new ongoing trials.. I'd wonder if this information could be shared with the agency to help firm AA decision.